These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 14988672)
1. Novel antibacterial agents for skin and skin structure infections. Schweiger ES; Weinberg JM J Am Acad Dermatol; 2004 Mar; 50(3):331-40; quiz 341-2. PubMed ID: 14988672 [TBL] [Abstract][Full Text] [Related]
2. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin. Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459 [TBL] [Abstract][Full Text] [Related]
3. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Wesson KM; Lerner DS; Silverberg NB; Weinberg JM Dis Mon; 2004 Jul; 50(7):395-406. PubMed ID: 15280870 [No Abstract] [Full Text] [Related]
4. Current and new antimicrobial agents. Eliopoulos GM Am Heart J; 2004 Apr; 147(4):587-92. PubMed ID: 15077072 [TBL] [Abstract][Full Text] [Related]
5. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology. Wesson KM; Lerner DS; Silverberg NB; Weinberg JM Clin Dermatol; 2003; 21(1):64-70. PubMed ID: 12609590 [No Abstract] [Full Text] [Related]
6. Treatment of infections caused by resistant Staphylococcus aureus. Anstead GM; Quinones-Nazario G; Lewis JS Methods Mol Biol; 2007; 391():227-58. PubMed ID: 18025681 [TBL] [Abstract][Full Text] [Related]
7. Role of linezolid in the treatment of complicated skin and soft tissue infections. Peppard WJ; Weigelt JA Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613 [TBL] [Abstract][Full Text] [Related]
9. Management of cSSTIs: the role of daptomycin. Garau J Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967 [TBL] [Abstract][Full Text] [Related]
11. Newer treatment options for skin and soft tissue infections. Raghavan M; Linden PK Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625 [TBL] [Abstract][Full Text] [Related]
12. Resistant pathogen-associated skin and skin-structure infections: antibiotic options. Curcio D Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1019-36. PubMed ID: 20818946 [TBL] [Abstract][Full Text] [Related]
13. [New anti-Gram+antibiotics: which role in infective endocarditis?]. Makinson A; Le Moing V Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):88-92. PubMed ID: 18395180 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Lee SY; Kuti JL; Nicolau DP Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Anstead GM; Owens AD Curr Opin Infect Dis; 2004 Dec; 17(6):549-55. PubMed ID: 15640709 [TBL] [Abstract][Full Text] [Related]
16. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
17. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Nailor MD; Sobel JD Infect Dis Clin North Am; 2009 Dec; 23(4):965-82, ix. PubMed ID: 19909893 [TBL] [Abstract][Full Text] [Related]
18. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Kern WV Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659 [TBL] [Abstract][Full Text] [Related]
19. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Schmidt-Ioanas M; de Roux A; Lode H Curr Opin Crit Care; 2005 Oct; 11(5):481-6. PubMed ID: 16175036 [TBL] [Abstract][Full Text] [Related]
20. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance. Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]